Loading
A phase 2 trial of Telisotuzumab adizutecan, Bevacizumab, Leucovorin in colorectal cancer, run by AbbVie, active and no longer recruiting.
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab is a phase 2 interventional study registered as NCT06107413 by AbbVie, with 280 participants planned, started 2023-11-12 and due to reach its primary completion in 2026-12. Interventions recorded: ABBV-400, Bevacizumab, Folinic Acid, Fluorouracil, Irinotecan. Conditions listed: Unresectable Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares Leucovorin (folinic acid), Fluorouracil (5-FU), Bevacizumab, Anti-angiogenic therapy.
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Fluorouracil (5-FU), Bevacizumab.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Anti-angiogenic therapy, Monoclonal antibodies.
Shares Leucovorin (folinic acid), Fluorouracil (5-FU), Bevacizumab, Anti-angiogenic therapy.